1 / 7

Screening for AF: Key Issues

How Much AF is Too Much AF? Do I Initiate Anticoagulation Based on AF Detected on Device Monitoring?. Kenneth W. Mahaffey, MD, FACC Professor of Medicine, Cardiology Faculty Associate Director, DCRI Director, DCRI MegaTrials & CEC Duke Clinical Research Institute Durham, NC.

fionan
Télécharger la présentation

Screening for AF: Key Issues

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. How Much AF is Too Much AF?Do I Initiate Anticoagulation Based on AF Detected on Device Monitoring? Kenneth W. Mahaffey, MD, FACCProfessor of Medicine, CardiologyFaculty Associate Director, DCRIDirector, DCRI MegaTrials & CEC Duke Clinical Research Institute Durham, NC

  2. DisclosuresConsultant Fees/HonorariaAdolor; Amgen; AstraZeneca; Bayer HealthCare; Biotronik, Inc.; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo, Inc.; Eli Lilly; Elsevier; Exeter Group; Forest; Genentech; Gilead; GlaxoSmithKline; Haemonetics; Johnson and Johnson; Medtronic; Merck and Co., Inc.; Novartis; Orexigen Therapeutics; Ortho-McNeil; Pfizer Inc; sanofi-aventis U.S. Inc.; Sun Pharma; Springer Publishing; WebMD Research/Research GrantsAbbott Vascular; Amgen; Amylin; AstraZeneca; Baxter; Bayer HealthCare; Boehringer Ingelheim; Bristol-Myers Squibb; Cordis; Daiichi Sankyo, Inc.; Edwards Lifesciences; Eli Lilly; GlaxoSmithKline; Guidant; Ikaria; INC Research; Johnson and Johnson; Kai Pharmaceuticals; Luitpold; Merck and Co., Inc.; Portola Pharmaceuticals; Pozen; Regado Biosciences; Roche; sanofi-aventis U.S. Inc.; Schering Plough; The Medicines Company

  3. Screening for AF:Key Issues • Predicting AF • Screening • Finding • Quantifying • Determining risk • Treating • Modifying outcomes

  4. ASSERT TrialStroke or Systemic Embolism 0.10 # at Risk Year 0.5 1.0 1.5 2.0 2.5 + 261 249 238 218 178 122 - 2,319 2,145 2,070 1,922 1,556 1,197 0.08 HR = 2.49 95% CI, 1.28-4.85 P = 0.007 Device-Detected Atrial TachyarrhythmiaDetected 0-3 months 0.06 Cumulative Hazard Rates 0.04 0.02 No Asymptomatic Atrial TachycardiaDetected 0-3 months 0.0 2.5 0 0.5 1.0 1.5 2.0 T0 at 3-month visit Years of Follow-up Healy JS, et al. N Engl J Med. 2012;366:120-129.

  5. TRENDS TrialAF Burden & Thromboembolic Events Glotzer TV, et al. Circ Arrhythm Electrophysiol. 2009;474-480.

  6. IMPACT TrialDevice Monitoring Guided Anticoagulation • Patient Population: • N = 2,718 • Dual-chamber ICD or CRT-D device • CHADS2 ≥ 1 • Primary endpoint = composite of stroke, systemic embolism and major bleeding • Hypothesis: • Initiation and withdrawal of anticoagulant therapy guided by ambulatory monitoring will improve clinical outcomes • Phase A (N = 227) completed 2009 • Phase B ongoing Group 1 (Intervention) Conventional follow-up + HM-guided anticoagulation Randomize 1:1 Conventional follow-up + physician-directed anticoagulation Group 2 (Control) 30m 6m 12m 24m 18m 36m Ip J, et al. Am Heart J. 2009;158:364-370.

  7. Summary • Type of AF or AF burden should not influence stroke prevention treatment strategy • Antithrombotic therapy for patients with AF should be guided by risk stratification based on validated prediction tools • Patients with history of AF in sinus rhythm are not necessarily low risk

More Related